Supplementary Table 1: Study quality assessment for the evidence base

Author, date / Abstract and Title / Introduction and aims / Method and data / Sampling / Data analysis / Ethics and bias / Findings / results / Transferability / Generalalizability / Implications and usefulness
Ahmad et al1 / Fair / Good / Fair / Fair / Very poor / Very poor / Fair / Fair / Fair
Atassi et al.2 / Good / Fair / Good / Fair / Very poor / Very poor / Fair / Fair / Fair
Carr et al.3 / Fair / Fair / Good / Poor / Very poor / Very poor / Good / Fair / Fair
Carr et al.4 / Good / Fair / Fair / Poor / Fair / Fair / Good / Fair / Fair
Donahue et al.5 / Good / Good / Good / Fair / Good / Very poor / Good / Fair / Good
Edeline et al.6 / Good / Good / Good / Fair / Good / Very poor / Good / Fair / Good
Gaba et al.7 / Good / Good / Good / Fair / Good / Very poor / Good / Fair / Fair
Garin et al.8 / Good / Good / Good / Poor / Good / Fair / Good / Fair / Fair
Goin et al.9 / Good / Good / Good / Fair / Good / Fair / Good / Fair / Fair
Hetta et al.10 / Good / Good / Good / Fair / Fair / Very poor / Good / Fair / Fair
Hilgard et al.11 / Fair / Good / Good / Fair / Good / Very poor / Good / Fair / Fair
Ibrahim et al.12 / Good / Good / Good / Fair / Good / Very poor / Good / Fair / Fair
Inarrairaegui et al.13 / Good / Good / Good / Fair / Good / Fair / Good / Fair / Good
Kooby et al.14 / Good / Good / Good / Poor / Good / Very poor / Good / Fair / Good
Kulik et al.15 / Good / Good / Good / Poor / Poor / Very poor / Good / Fair / Fair
Kulik et al.16 / Fair / Good / Good / Fair / Poor / Very poor / Good / Fair / Fair
Lambert et al.17 / Good / Good / Good / Fair / Fair / Very poor / Good / Fair / Fair
Lewandowski et al.18 / Fair / Good / Good / Poor / Good / Very poor / Good / Fair / Fair
Liu et al.19 / Fair / Good / Good / Fair / Fair / Very poor / Good / Fair / Fair
Mazzaferro et al.20 / Fair / Good / Good / Good / Good / Very poor / Good / Fair / Good
Pracht et al.21 / Fair / Good / Good / Poor / Good / Fair / Good / Fair / Fair
Salem et al.22 / Good / Good / Good / Fair / Good / Fair / Good / Fair / Good
Salem et al.23 / Good / Good / Good / Fair / Good / Fair / Good / Fair / Good
Salem et al.24 / Good / Good / Good / Poor / Good / Fair / Good / Fair / Good
Sangro et al.25 / Good / Good / Good / Fair / Very poor / Very poor / Good / Fair / Good
Sangro et al.26 / Good / Good / Good / Fair / Good / Very poor / Good / Fair / Fair
Strigari et al.27 / Good / Good / Good / Fair / Good / Very poor / Good / Fair / Fair
Vouche et al.28 / Fair / Good / Good / Fair / Good / Very poor / Good / Fair / Fair
Gramenzi et al.29 / Good / Good / Good / Good / Good / Fair / Good / Fair / Good
Khor et al.30 / Good / Good / Good / Fair / Good / Fair / Good / Fair / Good
Saxena et al.31 / Good / Good / Good / Fair / Good / Fair / Good / Fair / Good

References

1. Ahmad J, Rhee J, Carr BI. The effects of hepatic artery chemotherapy on viral hepatitis in patients with hepatocellular carcinoma. Digestive diseases and sciences. 2005;50(2):331-335.

2. Atassi B, Bangash AK, Lewandowski RJ, et al. Biliary sequelae following radioembolization with Yttrium-90 microspheres. J Vasc Interv Radiol. 2008;19(5):691-697.

3. Carr BI. Hepatic arterial 90Yttrium glass microspheres (Therasphere) for unresectable hepatocellular carcinoma: interim safety and survival data on 65 patients. Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society. 2004;10(2 Suppl 1):S107-110.

4. Carr BI, Metes DM. Peripheral blood lymphocyte depletion after hepatic arterial 90Yttrium microsphere therapy for hepatocellular carcinoma. International journal of radiation oncology, biology, physics. 2012;82(3):1179-1184.

5. Donahue LA, Kulik L, Baker T, et al. Yttrium-90 radioembolization for the treatment of unresectable hepatocellular carcinoma in patients with transjugular intrahepatic portosystemic shunts. J Vasc Interv Radiol. 2013;24(1):74-80.

6. Edeline J, Lenoir L, Boudjema K, et al. Volumetric changes after 90Y radioembolization for hepatocellular carcinoma in cirrhosis: An option to portal vein embolization in a preoperative setting? Annals of surgical oncology. 2013;20(8):2518-2525.

7. Gaba RC, Lewandowski RJ, Kulik LM, et al. Radiation lobectomy: Preliminary findings of hepatic volumetric response to lobar yttrium-90 radioembolization. Annals of surgical oncology. 2009;16(6):1587-1596.

8. Garin E, Lenoir L, Edeline J, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: A new personalized promising concept. European journal of nuclear medicine and molecular imaging. 2013;40(7):1057-1068.

9. Goin JE, Salem R, Carr BI, et al. Treatment of unresectable hepatocellular carcinoma with intrahepatic yttrium 90 microspheres: a risk-stratification analysis. J Vasc Interv Radiol. 2005;16(2 Pt 1):195-203.

10. Hetta OM, Hetta WM, Shebrya NH, El Ghazaly HA. Radioembolization with Yttrium-90 resin microspheres in treatment of HCC with or without PVT: Initial Egyptian experience. Egyptian Journal of Radiology and Nuclear Medicine. 2013;44(2):215-222.

11. Hilgard P, Hamami M, Fouly AE, et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology. 2010;52(5):1741-1749.

12. Ibrahim SM, Kulik L, Baker T, et al. Treating and downstaging hepatocellular carcinoma in the caudate lobe with yttrium-90 radioembolization. Cardiovascular and interventional radiology. 2012;35(5):1094-1101.

13. Inarrairaegui M, Thurston KG, Bilbao JI, et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol. 2010;21(8):1205-1212.

14. Kooby DA, Egnatashvili V, Srinivasan S, et al. Comparison of yttrium-90 radioembolization and transcatheter arterial chemoembolization for the treatment of unresectable hepatocellular carcinoma. Journal of vascular and interventional radiology : JVIR. 2010;21(2):224-230.

15. Kulik LM, Atassi B, Van Holsbeeck L, et al. Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: Downstaging to resection, RFA and bridge to transplantation. Journal of surgical oncology. 2006;94(7):572-586.

16. Kulik LM, Carr BI, Mulcahy MF, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47(1):71-81.

17. Lambert B, Sturm E, Mertens J, et al. Intra-arterial treatment with 90Y microspheres for hepatocellular carcinoma: 4 years experience at the Ghent University Hospital. European journal of nuclear medicine and molecular imaging. 2011;38(12):2117-2124.

18. Lewandowski RJ, Kulik LM, Riaz A, et al. A comparative analysis of transarterial downstaging for hepatocellular carcinoma: Chemoembolization versus radioembolization. American Journal of Transplantation. 2009;9(8):1920-1928.

19. Liu MD, Uaje MB, Al-Ghazi MS, et al. Use of Yttrium-90 TheraSphere for the treatment of unresectable hepatocellular carcinoma. The American surgeon. 2004;70(11):947-953.

20. Mazzaferro V, Sposito C, Bhoori S, et al. Yttrium-90 radioembolization for intermediate-advanced hepatocellular carcinoma: A phase 2 study. Hepatology. 2013;57(5):1826-1837.

21. Pracht M, Edeline J, Lenoir L, et al. Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: preliminary results. International journal of hepatology. 2013;2013(827649):827649.

22. Salem R, Lewandowski RJ, Kulik L, et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology. 2011;140(2):497-507.

23. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. Journal of vascular and interventional radiology : JVIR. 2005;16(12):1627-1639.

24. Salem R, Lewandowski RJ, Mulcahy MF, et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology. 2010;138(1):52-64.

25. Sangro B, Bilbao JI, Boan J, et al. Radioembolization using 90Y-resin microspheres for patients with advanced hepatocellular carcinoma. Int J Radiat Oncol. 2006;66(3):792-800.

26. Sangro B, Carpanese L, Cianni R, et al. Survival after Yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: A European evaluation. Hepatology. 2011;54(3):868-878.

27. Strigari L, Sciuto R, Rea S, et al. Efficacy and toxicity related to treatment of hepatocellular carcinoma with 90Y-SIR spheres: radiobiologic considerations. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010;51(9):1377-1385.

28. Vouche M, Habib A, Ward TJ, et al. Unresectable solitary hepatocellular carcinoma not amenable to radiofrequency ablation: multicenter radiology-pathology correlation and survival of radiation segmentectomy. Hepatology. 2014;60(1):192-201.

29. Gramenzi A, Golfieri R, Mosconi C, et al. Yttrium-90 radioembolization vs sorafenib for intermediate-locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis. Liver international : official journal of the International Association for the Study of the Liver. 2014.

30. Khor AYK, Toh Y, Allen JC, et al. Survival and pattern of tumor progression with yttrium-90 microsphere radioembolization in predominantly hepatitis B Asian patients with hepatocellular carcinoma. Hepatology International. 2014;8(3):395-404.

31. Saxena A, Meteling B, Kapoor J, et al. Yttrium-90 radioembolization is a safe and effective treatment for unresectable hepatocellular carcinoma: A single centre experience of 45 consecutive patients. International journal of surgery. 2014.